Previous 10 | Next 10 |
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, mar...
Oragenics ( NYSE: OGEN ) said Friday its board of directors approved a 1-for-60 reverse stock split of the company outstanding shares. Shares +54.5% at 22 cents in after market hours. After the reverse stock split takes effect, the number of authorized shares will be reduc...
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) , a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the “Board”) on December 22, 2022 approved a 1-for-60 rev...
Nanocap biotech Oragenics ( NYSE: OGEN ) added ~37% pre-market Thursday issuing pre-clinical findings from a final toxicology report to highlight the safety of its intranasal vaccine candidate for COVID-19, NT-CoV2-1. Citing a toxicology study for NT-CoV2-1 in rabbits, Oragenics (...
No toxicity found in NT-CoV2-1, supports regulatory filing for Phase 1 study Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced result...
Oragenics ( NYSE: OGEN ) said Tuesday it received a notice from NYSE American as it is not in compliance with continued listing standards. The company has until June 19 to regain compliance. This could be extended to its next annual shareholder meeting. For further deta...
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) , a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board...
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami. ...
N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company ...
News, Short Squeeze, Breakout and More Instantly...
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has developed a new formulation for its novel neurosteroid. Oragenics’...
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concu...